Plasma Volume Determination by 99mTc-labeled Albumin and 125I-labeled Albumin
|Healthy||Radiation: Plasma volume determination (99mTc-albumin) Radiation: Plasma volume determination (125I-albumin)|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Basic Science
|Official Title:||Comparison of Plasma Volume Determination by 99mTc-labeled Albumin and 125I-labeled Albumin|
- Plasma volume determined by 99mTc-labeled albumin and 125I-labeled albumin [ Time Frame: January 2011 ]
- Rates of loss of 99mTc-labeled albumin and 125I-labeled albumin from the circulation [ Time Frame: January 2011 ]
|Study Start Date:||January 2012|
|Study Completion Date:||December 2012|
|Primary Completion Date:||January 2012 (Final data collection date for primary outcome measure)|
Radiation: Plasma volume determination (99mTc-albumin)
For many years, radioiodinated albumin has been "the golden standard" for measurement of plasma volume. There are a number of clinical situations in which a nuclide with a shorter half-life would be preferred. Furthermore, due to periodic lapses in the availability in the delivery of 125I-labeled albumin, there is a need to evaluate another nuclide as a tracer for plasma volume determination.
99mTc-labeled albumin is easily prepared by a simple and reproducible method with a high labeling efficiency and short half-life.
In this study, we want to compare plasma volume determined by 99mTc-labeled albumin with plasma volume determined by 125I-albumin (golden standard). In both procedures, plasma volume is estimated from multiple postinjection samples for accurate zero-time extrapolation in order to correct for leakage of labeled albumin from the vascular compartment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01049087
|University Hospital Koge, Department of Clinical Physiology and Nuclear Medicine|
|Koge, Denmark, DK-4600|
|Study Chair:||Steen Levin, MD, DMSc||University Hospital Koge|
|Principal Investigator:||Peter K Bonfils, MD||University Hospital Koge|
|Study Director:||Knud H Stokholm, MD||University Hospital Koge|